ptdss1 Antibody

What is PTDSS1 and why is it important in cellular research?

PTDSS1 (phosphatidylserine synthase 1) is an enzyme that catalyzes the production of phosphatidylserine (PS), a critical membrane phospholipid involved in numerous cellular processes including development, cell signaling, apoptosis, and blood coagulation. The enzyme plays a fundamental role in phospholipid metabolism and membrane composition regulation. Understanding PTDSS1 function is essential as mutations in this gene have been linked to various conditions including developmental delay and certain forms of cancer. For researchers, PTDSS1 represents an important target for investigating lipid metabolism disorders and potential therapeutic interventions .

How should PTDSS1 antibodies be validated before experimental use?

Proper validation of PTDSS1 antibodies is crucial for experimental reliability. Begin with Western blot analysis using positive controls (cells known to express PTDSS1) and negative controls (PTDSS1 knockout cells or cells treated with PTDSS1-specific siRNA). Confirm antibody specificity by verifying that the detected protein band matches the expected molecular weight of PTDSS1. For immunoprecipitation experiments, perform reciprocal IPs and confirm results with alternative antibodies. For immunocytochemistry applications, compare staining patterns with subcellular localization data from databases and published literature. Consider using vinculin as an internal reference protein rather than GAPDH (which might be influenced by metabolism) or tubulin (which has a molecular weight similar to PTDSS1) .

What are key considerations when selecting between different PTDSS1 antibody formats?

The selection of PTDSS1 antibody formats depends on the experimental application. For direct detection methods like Western blots or ELISA, conjugated antibodies (e.g., HRP-conjugated antibodies like ABIN7163253) eliminate the need for secondary antibodies, reducing background and cross-reactivity issues . For applications requiring signal amplification like immunohistochemistry, unconjugated primary antibodies followed by labeled secondary antibodies may be preferable. Consider the specific epitope targeted by the antibody - those targeting highly conserved regions (e.g., AA 1-35) may be useful across multiple species. Additionally, evaluate the clonality of the antibody, as monoclonal antibodies provide consistent results across experiments but might miss isoforms or post-translationally modified versions of PTDSS1.

What are the optimal conditions for Western blot detection of PTDSS1?

For optimal Western blot detection of PTDSS1, use a membrane transfer protocol optimized for transmembrane proteins. After transfer, block the membrane thoroughly to prevent non-specific binding. Incubate with a primary anti-PTDSS1 antibody (such as ab237019 from Abcam) overnight at 4°C, followed by washing with TBST and incubation with appropriate HRP-conjugated secondary antibodies for 2 hours at room temperature. For internal reference, use vinculin (E1E9V, #13901, CST) rather than GAPDH or tubulin since vinculin is a cell skeleton-related protein with stable expression that won't be affected by metabolic changes. Visualize using enhanced chemiluminescence (ECL) detection reagents and quantify protein expression through densitometry analysis, normalizing to vinculin expression .

How can researchers effectively measure PTDSS1 enzyme activity in cell culture?

To measure PTDSS1 enzyme activity in cultured cells, researchers can employ radiolabeling techniques using C14-serine incorporation assays. First, express wild-type and/or mutant PTDSS1 in appropriate expression vectors (such as pEGFP-N2) in cells like HEK293-AT1. After transfection, confirm protein expression by Western blot using anti-GFP or anti-PTDSS1 antibodies. Then incubate cells with C14-labeled serine and measure its incorporation into phosphatidylserine (PS) and downstream phosphatidylethanolamine (PE) via thin-layer chromatography followed by autoradiography or phosphorimaging. Quantify the labeled spots to determine relative enzymatic activity. For inhibitor studies, include appropriate controls such as cells treated with PTDSS1 inhibitors (e.g., DS68591889) or PI4KA inhibitors (e.g., A1) to differentiate between specific enzymatic activities .

What approaches can be used to study PTDSS1 localization in cellular compartments?

To study PTDSS1 localization, employ both biochemical fractionation and imaging approaches. For subcellular fractionation, use differential centrifugation to separate cellular compartments, followed by Western blotting with anti-PTDSS1 antibodies. For imaging, perform immunofluorescence using specific anti-PTDSS1 antibodies coupled with markers for different organelles (ER, Golgi, plasma membrane). For live-cell imaging, express PTDSS1-GFP fusion proteins and examine their localization in real-time. Additionally, use proximity ligation assays to detect interactions between PTDSS1 and other proteins in specific subcellular locations. To study the role of PTDSS1 at membrane contact sites, co-localization studies with markers of these specialized regions (such as VAPA/B for ER-PM contacts) can be performed alongside PTDSS1 staining. For studies examining phospholipid metabolism, fluorescent probes for specific lipids (e.g., EGFP-2xPH evectin2 for PS or EGFP-2xP4M SidM for PI4P) can be used to visualize lipid distributions before and after PTDSS1 manipulation .

How do different PTDSS1 mutations lead to distinct clinical phenotypes?

PTDSS1 mutations result in strikingly different phenotypes depending on whether they cause gain-of-function or loss-of-function effects. Gain-of-function missense mutations in PTDSS1 lead to Lenz-Majewski hyperostotic dwarfism (LMHD), characterized by sclerosing bone dysplasia, intellectual disability, and distinct craniofacial, dental, cutaneous, and distal limb anomalies. These mutations cause uncontrolled high constitutive activity of the PSS1 enzyme, resulting in dysregulated PS metabolism. In contrast, loss-of-function variants, such as the novel heterozygous de novo variant p.(Leu137Phe), are associated with milder phenotypes including developmental delay without the characteristic features of LMHD. Functional analysis of this variant demonstrated reduced incorporation of C14-serine into PS and PE, confirming its loss-of-function nature. This distinct difference in clinical manifestation highlights the complex role of PTDSS1 in development and the importance of precisely balanced PS levels for normal cellular function .

What is the evidence supporting PTDSS1's role in neurodevelopmental disorders?

Evidence for PTDSS1's role in neurodevelopmental disorders comes from both clinical and experimental data. Clinically, a heterozygous de novo loss-of-function variant p.(Leu137Phe) in PTDSS1 was identified in a child with mild-to-moderate developmental delay. This variant is absent from population databases (gnomAD), suggesting its pathogenicity. Supporting this, PTDSS1 is a constrained gene with an observed/expected ratio of 0.25 for loss-of-function variants and a scaled Combined Annotation Dependent Depletion (CADD) score of 25.8 for the p.(Leu137Phe) variant, indicating likely pathogenicity. Additionally, PTDSS1 has been previously identified as a candidate gene for autism spectrum disorder (ASD) based on a copy number variant (CNV) affecting the gene in a patient with autism. This individual had a maternally inherited 152kb gain of 8q22.1 impacting PTDSS1 and three other genes. These findings suggest that proper phosphatidylserine metabolism, regulated by PTDSS1, is critical for normal neurodevelopment .

How does PTDSS1 contribute to cancer development and progression?

PTDSS1 contributes to cancer development and progression through multiple mechanisms related to lipid metabolism. In B cell lymphomas, PTDSS1 has been identified as a key metabolic vulnerability, particularly in B cell receptor (BCR)-positive lymphomas. Inhibition of PTDSS1 using specific inhibitors like DS68591889 causes an imbalanced phospholipid metabolism via membrane contact-based lipid transfer machinery. This leads to aberrant BCR hyperactivation and ultimately cell death. In lung adenocarcinoma (LUAD), PTDSS1 acts as an oncogene, with knockdown experiments showing decreased cell proliferation and increased apoptosis in LUAD cell lines. Bioinformatic analyses of multiple datasets, including both bulk and single-cell RNA sequencing data, have established PTDSS1 as part of a lipid metabolism-related gene signature with significant prognostic value in LUAD. This signature has potential for predicting both prognosis and response to immunotherapy in LUAD patients, highlighting PTDSS1's role in cancer metabolism and potential as a therapeutic target .

How does PTDSS1 inhibition affect phosphoinositide metabolism and cellular signaling?

PTDSS1 inhibition dramatically alters phosphoinositide metabolism, with significant downstream effects on cellular signaling pathways. When PTDSS1 is inhibited or knocked out, there is a significant increase in phosphatidylinositol-4-phosphate (PI4P) levels at the plasma membrane, as demonstrated by both biochemical measurements and localization studies using fluorescent PI4P probes (EGFP-2xP4M SidM). This elevated PI4P leads to increased PI(4,5)P2 levels, which serves as a substrate for phospholipase C gamma 2 (PLCγ2). In B cell receptor (BCR) signaling, PTDSS1 inhibition enhances PLCγ2 activity, resulting in elevated IP3 production (measured as IP1) and significantly amplified calcium signaling. This enhanced calcium response can be reversed by adding exogenous phosphatidylserine or by inhibiting PI4KIIIα (which converts PI to PI4P). These findings indicate that PTDSS1 primarily controls the plasma membrane PI4P pool, thereby regulating downstream phosphoinositide-dependent signaling pathways, particularly those involved in BCR activation and calcium mobilization .

What role does PTDSS1 play in immunotherapy response prediction?

PTDSS1 plays a significant role in predicting immunotherapy responses, particularly in lung adenocarcinoma (LUAD). As part of a lipid metabolism-related gene signature, PTDSS1 expression levels contribute to a risk score model ("Lipid-score") that has been validated for its ability to predict patient responses to PD-1/PD-L1 immunotherapy. Researchers have analyzed multiple immunotherapy datasets (Phs000452.v3, PMID: 26359337, PMID: 32472114, PRJEB23709) and found significant correlations between the Lipid-score (which includes PTDSS1) and clinical benefit from immunotherapy. Patients can be stratified into "Benefit" and "NonBenefit" groups based on this score, with statistical differences determined via Wilcoxon test. The mechanistic basis for this correlation likely involves PTDSS1's impact on tumor cell metabolism and membrane composition, which subsequently affects immune cell interactions and anti-tumor immune responses. This finding suggests that PTDSS1 expression analysis could be incorporated into predictive biomarker panels for immunotherapy response in LUAD and potentially other cancer types .

What are the challenges in developing specific inhibitors of PTDSS1 for research applications?

Developing specific PTDSS1 inhibitors presents several significant challenges that researchers must address. First, achieving specificity is complicated by the existence of a related enzyme, PTDSS2, with overlapping function. Current inhibitors like DS68591889 must be carefully evaluated for their selectivity profile using cell-free PTDSS assays. Second, membrane localization of PTDSS1 necessitates that inhibitors have appropriate physicochemical properties to reach their target at membrane contact sites. Third, researchers must carefully assess the downstream metabolic consequences of PTDSS1 inhibition, as it affects not only PS levels but also PE, PI, PG, PA, and sphingomyelin levels. Fourth, due to PTDSS1's role in normal cellular functions, inhibitors may exhibit toxicity in non-target tissues, requiring careful dose optimization for research applications. Finally, cell-type specific responses to PTDSS1 inhibition (e.g., particular sensitivity in BCR-positive B cell lymphomas) means that researchers must evaluate efficacy across multiple cellular models. To address these challenges, researchers should employ multiparametric assessment of inhibitor effects, including lipidomic profiling, cell viability across diverse cell lines, and pathway-specific readouts such as calcium signaling after BCR stimulation .

How can researchers effectively design PTDSS1 knockdown or knockout experiments?

To effectively design PTDSS1 knockdown or knockout experiments, researchers should employ a multi-layered strategy. For transient knockdown, use siRNA or shRNA targeting conserved regions of PTDSS1 with careful design to avoid off-target effects. For stable knockdown, lentiviral shRNA constructs provide consistent expression. For complete knockout, CRISPR-Cas9 technology with carefully designed guide RNAs targeting critical exons yields the most definitive results. Include appropriate controls such as scrambled siRNA/shRNA or non-targeting gRNAs. Validation of knockdown/knockout efficiency is crucial and should be performed at both mRNA level (RT-qPCR) and protein level (Western blot using specific anti-PTDSS1 antibodies). Importantly, researchers should assess the functional consequences of PTDSS1 depletion through lipidomic analysis (measuring PS and PE levels) and phenotypic assays such as proliferation, apoptosis, and cell-type specific functional assays. For cancer cell studies, clone formation assays, EDU incorporation, and flow cytometry for apoptosis markers provide critical insights into the effects of PTDSS1 depletion, as demonstrated in lung adenocarcinoma studies .

What controls should be included when studying gain-of-function versus loss-of-function PTDSS1 variants?

When studying PTDSS1 variants, a comprehensive set of controls is essential for accurate interpretation. For gain-of-function studies, include wild-type PTDSS1, empty vector controls, and known gain-of-function variants like P269S as positive controls. For loss-of-function studies, include wild-type PTDSS1, empty vector controls, and if possible, known loss-of-function variants like p.(Leu137Phe). When expressing PTDSS1 variants, verify comparable expression levels through Western blot. Functional assays should include enzymatic activity measurements using C14-serine incorporation into PS and PE by intact cells, with quantification of labeled lipids. To confirm phenotype specificity, conduct rescue experiments by adding back exogenous PS (e.g., C36:2-PS) but not other phospholipids like PC (C36:2-PC). For cellular phenotypes resulting from PTDSS1 mutations, include both biochemical assays (e.g., calcium signaling using Fura-2 ratiometric probes) and biological assays (e.g., measuring apoptosis through active caspase-3 detection). Together, these controls ensure that observed phenotypes are specifically attributable to alterations in PTDSS1 function rather than experimental artifacts .

How can researchers reconcile contradictory results in PTDSS1 functional studies?

When faced with contradictory results in PTDSS1 functional studies, researchers should systematically evaluate several factors that might contribute to discrepancies. First, consider cell type specificity, as PTDSS1 function may vary significantly between different cell types. For instance, B cell lymphomas show particular sensitivity to PTDSS1 inhibition compared to other cancer types. Second, examine the methodological differences between studies, including the specific techniques used to measure PTDSS1 activity or expression, and the conditions under which assays were performed. Third, evaluate the specific PTDSS1 variants or inhibition approaches used, as different mutations can lead to dramatically different phenotypes (gain-of-function versus loss-of-function). Fourth, consider the complex interplay between PTDSS1 and other lipid metabolism enzymes, as compensatory mechanisms may exist. To reconcile contradictions, perform side-by-side comparisons using multiple methodologies, include appropriate positive and negative controls, and conduct dose-response or time-course experiments to capture dynamic effects. Additionally, validate key findings using orthogonal approaches and consider genetic background effects that might influence PTDSS1 function or its consequences for cellular physiology .